Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
28.84
-0.26 (-0.89%)
At close: Oct 16, 2026, 4:00 PM EDT
28.37
-0.47 (-1.64%)
After-hours: Oct 16, 2026, 7:58 PM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Arcutis Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $38.38. The average 1-year stock price forecast is 33.08% higher than the current stock price, while the lowest is $34 (+17.89%) and the highest is $48 (+66.44%).
Price Target: $38.38 (+33.08%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 4 | 5 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $48 | Buy | Initiates | $48 | +66.44% | Oct 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $34 | Buy | Reiterates | $34 | +17.89% | Aug 11, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Reiterates $34 → $38 | Buy | Reiterates | $34 → $38 | +31.76% | Aug 6, 2026 |
| Needham | Needham | Buy Reiterates $40 | Buy | Reiterates | $40 | +38.70% | Aug 6, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $35 → $38 | Buy | Reiterates | $35 → $38 | +31.76% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
537.81M
from 376.07M
Increased by 43.01%
Revenue Next Year
686.80M
from 537.81M
Increased by 27.70%
EPS This Year
0.43
from -0.13
EPS Next Year
1.27
from 0.43
Increased by 193.43%
EPS and Forward PE are based on non-GAAP adjusted numbers.